Physician profile
Archna Sinha
NPI 1447572607
$765.50
in general payments reported to CMS, 2019-2025
11 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.63 · 2020: $47.63 · 2022: $169 · 2023: $84.48 · 2024: $164 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $235.69 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $122.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.49 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $87.47 | 2025 | |
| Abbvie INC. | $62.00 | 2023-2024 | Teflaro |
| Pfizer INC. | $39.12 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2020-2022 | |
| Urogen Pharma, INC. | $25.99 | 2025 | |
| Inspire Medical Systems, INC. | $22.12 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $21.10 | 2023 | Dificid, Zerbaxa |
| Allergan, INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archna Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.